Inovio Pharmaceuticals’ VGX-3100 therapeutic synthetic cancer vaccine has demonstrated that a DNA-based therapeutic vaccine can produce immune responses to kill target cells.
The clinical results indicate that its VGX-3100 therapeutic synthetic vaccine is capable of driving immune responses to antigens from high-risk types of human papilloma virus (HPV) infection and immune responses displayed a killing effect on cells changed by HPV into precancerous dysplasias.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Inovio president and CEO Dr. Joseph Kim said that the results indicate that a DNA-based immune therapy can generate potent and durable T-cell responses in people.
"Our ongoing phase II efficacy trial is designed to show that the immune responses seen in this study, in particular the generation of killer T-cell responses, may reverse cervical disease caused by chronic HPV infection," Dr. Kim added.
"The type of T-cell killing activity seen in this new data provides a growing foundation for efficacy trials focused on the treatment of HPV-associated cancers including cervical, head and neck, and anogenital cancers."
According to the phase I trial study data, 100% of patients (18 of 18) demonstrated antigen-specific antibody responses to Inovio’s vaccine, while 78% showed T-cell responses in the validated ELISpot assay.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataT-cell immunity tests measured the ability of CD8+ T-cells from vaccinated patients to kill cells displaying HPV antigens on their surface, 91% of patients who developed T-cell responses showed the presence of CD8+ T-cells capable of this type of killing activity.
A current phase II trial is assessing the ability of its DNA-based VGX-3100 to treat cervical dysplasias caused by HPV infection.
